Lynparza (olaparib tablets – AstraZeneca) — Cigna
Breast Cancer – Adjuvant Therapy
Initial criteria
- Patient is age ≥ 18 years
- Patient has germline BRCA mutation-positive breast cancer
- Patient has HER2-negative breast cancer
- Patient has tried neoadjuvant or adjuvant therapy
Approval duration
1 year